Benefits
NAD+ restoration
NMN is rapidly converted to NAD+ in cells, restoring levels that decline 40–50% between ages 40 and 60. Higher NAD+ supports mitochondrial efficiency, DNA repair, and metabolic signaling.
Metabolic health
Human trials show NMN supplementation improves insulin sensitivity, reduces liver fat, and improves skeletal muscle insulin signaling — effects mediated through NAD+-dependent SIRT1 activation.
Muscle function and endurance
RCT in older adults showed NMN improved muscle strength, walking speed, and grip strength over 12 weeks, with effects correlating with blood NAD+ increases.
Cognitive support
Preclinical studies show NAD+ restoration improves neuronal function, reduces neuroinflammation, and supports DNA repair in brain cells. Human cognitive trial data is emerging.
Mechanism of action
NAD+ biosynthesis via salvage pathway
NMN is phosphorylated by NMN adenylyltransferases (NMNATs) to directly produce NAD+. This bypasses rate-limiting steps in other NAD+ precursor pathways, making NMN one of the most efficient NAD+ boosters.
Sirtuin activation
Elevated NAD+ activates sirtuins (SIRT1–7), a family of NAD+-dependent deacetylases that regulate gene expression, mitochondrial biogenesis, inflammation, and stress resistance — key longevity pathways.
PARP-1 support for DNA repair
NAD+ is consumed by PARP-1 during DNA repair. Restoring NAD+ ensures adequate substrate for DNA damage repair, reducing genomic instability associated with aging.
Clinical trials
RCT in 42 older adults (65+) receiving 250 mg/day NMN vs placebo for 12 weeks. Outcomes: NAD+ metabolites, grip strength, walking speed, timed chair stand. (Yamane et al. 2022, GeroScience)
42 older adults aged 65+. 12-week intervention.
NMN increased blood NAD+ metabolites. Improved grip strength, walking speed, timed chair-stand test vs placebo. Note: small trial; first-generation human NMN data; effect sizes modest. NMN's evidence base is much smaller than NR's.
First human clinical trial of oral NMN: single doses of 100, 250, 500 mg in 10 healthy men. Outcomes: blood NAD+ metabolites, vital signs, safety. (Irie et al. 2020, Endocr J)
10 healthy men. Acute single-dose PK.
All doses safely increased blood NAD+ metabolites within 2-3 hours. No adverse effects on vital signs or metabolic markers. Established baseline NMN safety. CRITICAL CAVEAT: very small trial (n=10), single dose — NOT efficacy data, just safety/PK.